Bioregenx (BRGX) Return on Sales (2022 - 2026)

Bioregenx's Return on Sales history runs 5 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 10.0% increase from a year earlier, with the FY2025 full-year figure at 0.02%, up 8.0% from the prior year.
• Return on Sales improved to 0.0% in Q1 2026 per BRGX's latest filing, from 0.03% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q3 2023 and bottomed at 0.39% in Q4 2024.
• The 5-year median for Return on Sales is 0.01% (2022), against an average of 0.04%.
• Across the five-year window, Return on Sales sank 39 bps in 2024 and surged 37 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then fell by 21 bps to 0.01% in 2023, then slumped by 5115 bps to 0.39% in 2024, then surged by 93 bps to 0.03% in 2025, then jumped by 89 bps to 0.0% in 2026.
• Per Business Quant, the three latest BRGX Return on Sales figures stand at 0.0% (Q1 2026), 0.03% (Q4 2025), and 0.0% (Q3 2025).